«ТРОМБОЗ, ГЕМОСТАЗ и РЕОЛОГИЯ»

научно-практический журнал

ISSN 2078–1008 (Print)


Мы обновили сайт, чтобы он стал удобнее и функциональнее. До окончания обновления, более ранние выпуски смотрите здесь, актуальную информацию и свежие выпуски - на новой версии сайта.
—

Тромбоз, гемостаз и реология. — 2010. — №4(44). — С. 31.

Обзор литературы

УДК 616-005.6:615.038:615.074

Новые оральные антикоагулянты

Н. Г. Хорев1,2, А. П. Момот1, Д. А. Залозный2

Алтайский филиал Гематологического научного центра РАМН1; Кафедра факультетской хирургии им. проф. И. И. Неймарка с курсом хирургии ФПК и ППС ГОУ ВПО АГМУ Росздрава2; Барнаул, Россия

Антикоагулянты являются одними из наиболее часто используемых лекарственных препаратов в различных областях клинической медицины. Они включают средства, которые влияют на гемостаз и используются для предотвращения или лечения артериальных или венозных тромбозов и тромбоэмболий. Знание их свойств и навыки терапевтического применения необходимы, чтобы достигнуть максимальной пользы и ограничить частоту осложнений, связанных с кровотечениями. Настоящий обзор посвящен практическим вопросам использования некоторых новых антикоагулянтов, в том числе для перорального приема, которые недавно были введены в клиническую практику, а также тех из них, которые находятся на разных стадиях клинических испытаний.

Ключевые слова:  профилактика тромбозов — артропластика — оральные антикоагулянты.

Для корреспонденции:
Момот Андрей Павлович — д.м.н., профессор, директор Алтайского филиала ГНЦ РАМН.
Адрес: 656024, Барнаул, ул. Ляпидевского, д. 1.
Телефон: (3852) 68-98-00 (р.)
E-mail: xyzan@yandex.ru

Статья поступила 23.10.2010, принята к печати 21.12.2010.

NEW ORAL ANTICOAGULANTS

N. G. Khorev1,2, A. P. Momot1, D. A. Zaloznyy2

Altai Branch of Hematological Research Center (HRC) RAMS1; Department of surgery prof. I. I. Nejmarka ROSZDRAV AGMU2; Barnaul, Russia

Anticoagulants are one of the most commonly used drugs in various fi elds of clinical medicine. They include drugs that infl uence on hemostasis and are used to prevent or treat arterial or venous thrombosis and tromboembolism. The knowledge of their properties and the skills of their therapeutic application are necessary to achieve the maximum benefi ts and limit the frequency of bleeding complications. This overview focuses on the practical use of some new anticoagulants, including oral medicines which have been recently introduced into clinical practice as well as those which are in various stages of clinical trials.

Key words: prophylaxis of thrombosis — arthroplasty — oral anticoagulants.

Литература/References

  1. Last J. A. Th e Missing Link: Th e Story of Karl Paul Link // Toxicol. Sci. — 2002. — Vol. 66. — P. 4–6.
  2. Whitlon D. S., Sadowski J. A., Suttie J. W. Mechanism of coumarin action: signifi cance of vitamin K epoxide reductase inhibition // Biochemistry. — 1978. — Vol. 17. — P. 1371– 1377.
  3. Kristiansen C., Lassen J. F., Dahler-Eriksen B. S. et al. Evaluation of a simple dosage scheme for transition from phenprocoumon to warfarin in oral anticoagulation // Th romb. Res. — 2000. — Vol. 98. — P. 157–163.
  4. van Geest-Daalderop J. H., Pequeriaux N. C., van den Besselaar A. M. Variability of INR in patients on stable longterm treatment with phenprocoumon and acenocoumarol and implications for analytical quality requirements // Th romb. Haemost. — 2009. — Vol. 102. — P. 588–592.
  5. Stehle S., Kirchheiner J., Lazar A. et al. Pharmacogenetics of oral anticoagulants: a basis for dose individualization // Clin. Pharmacokinet. — 2008. — Vol. 47. — P. 565–594.
  6. Perez-Andreu V., Roldan V., Anton A. I. et al. Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy // Blood. — 2009. — Vol. 113. — P. 4977–4979.
  7. Klein T. E., Altman R. B., Eriksson N. et al. Estimation of the warfarin dose with clinical and pharmacogenetic data // N. Engl. J. Med. — 2009. — Vol. 360. — P. 753–764.
  8. Agnelli G., Eriksson B. I., Cohen A. T. et al. Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran // Th romb. Res. — 2009. — Vol. 123. — P. 488–497.
  9. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate // Clin. Pharmacokinet. — 2008. — Vol. 47. — P. 285–295.
  10. Stangier J., Stahle H., Rathgen K. et al. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not aff ected by moderate hepatic impairment // Clin. Pharmacol. — 2008. — Vol. 48. — P. 1411–1419.
  11. Eriksson B. I., Dahl O. E., Rosencher N. et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial // Lancet. — 2007. — Vol. 370. — P. 949–956.
  12. Eriksson B. I., Dahl O. E., Rosencher N. et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism aft er total knee replacement: the RE-MODEL randomized trial // Th romb. Haemost. — 2007. — Vol. 5. — P. 2178–2185.
  13. Ginsberg J. S., Davidson B. L., Comp P. C. et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism aft er knee arthroplasty surgery // Arthroplasty. — 2009. — Vol. 24. — P. 1–9.
  14. Connolly S. J., Ezekowitz M. D., Yusuf S. et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation // N. Engl. J. Med. — 2009. — Vol. 361. — P. 1139–1151.
  15. Diener H-C., Connolly S., Ezekowitz M. D. et al. Dabigatran Compared to Warfarin in Patients with Atrial Fibrillation and Prior TIA or Stroke // RE-LY American Stroke Association International Stroke Conference 2010. — Late Braking Science 2010. — Abstract 195.
  16. Healey J. S., Eikelboom J., Wallentin L. et al. Eff ect of age and renal function on the risks of stroke and major bleeding with dabigatran compared to warfarin: An analysis from the RE-LY study // Am. Coll. Cardiol. — 2010. — Vol. 55. — P. 1078–1120.
  17. Koti M. J., Parekh A., Connolly S. J. et al. Dabigatran versus warfarin in patients with atrial fi brillation — An analysis of patients undergoing cardioversion // Am. Coll. Cardiol. — 2010. — Vol. 55. — P. 1078–1124.
  18. Oldgren J., Alings M., Darius H. et al. Dabigatran versus warfarin in atrial fi brillation patients with low, moderate and high CHADS2 score: A RE-LY subgroup analysis // Am. Coll. Cardiol. — 2010. — Vol. 55. — P. 903–904.
  19. Stangier J., Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor // Clin. Appl. Th romb. Hemost. — 2009 [epub. ahead of print].
  20. Schulman S., Kearon C., Kakkar A. K. et al. Dabigatran versus Warfarin in the Treatment of Acute Venous Th romboembolism // N. Engl. J. Med. — 2009. — Vol. 361. — P. 2342–2352.
  21. Oldgren J., Budaj A., Granger C. et al. Randomised dabigatran etexilate dose fi nding study in patients with acute coronary syndromes post index event with additional risk factors for cardiovascular complications also receiving aspirin and clopidogrel (RE-DEEM) // Circulation. — 2009. — Vol. 120. — P. 2160–2161. — Abstract 165.
  22. Lip G. Y., Rasmussen L. H., Olsson S. B. et al. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists // Eur. Heart. J. — 2009. — Vol. 30. — P. 2897– 2907.
  23. Olsson S. B., Rasmussen L. H., Tveit A. et al. Safety and tolerability of an immediate release formulation of the oral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fi - brillation // Th romb. Haemost. — 2010. — Vol. 103. — P. 604–612.
  24. Perzborn E., Strassburger J., Wilmen A. et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59– 7939 an oral, direct Factor Xa inhibitor // Th romb. Haemost. — 2005. — Vol. 3. — P. 514–521.
  25. Kubitza D., Becka M., Wensing G. et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59–7939 an oral, direct Factor Xa inhibitor aft er multiple dosing in healthy male subjects // Eur. J. Clin. Pharmacol. — 2005. — Vol. 61. — P. 873–880.
  26. Kubitza D., Becka M., Zuehlsdorf M. et al. Eff ect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59–7939 (rivaroxaban), an oral, direct factor Xa inhibitor in healthy subjects // Clin. Pharmacol. — 2006. — Vol. 46. — P. 549–558.
  27. Kubitza D., Becka M., Roth A. et al. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects // Curr. Med. Res. Opin. — 2008. — Vol. 24. — P. 2757–2765.
  28. Haas S. Rivaroxaban — an oral, direct Factor Xa inhibitor: lessons from a broad clinical study programme // Eur. J. Haematol. — 2009. — Vol. 82. — P. 339–349.
  29. Eriksson B. I., Borris L. C., Friedman R. J. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis aft er hip arthroplasty // N. Engl. J. Med. — 2008. — Vol. 358. — P. 2765–2775.
  30. Kakkar A. K., Brenner B., Dahl O. E. et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism aft er total hip arthroplasty: a double-blind, randomised controlled trial // Lancet. — 2008. — Vol. 372. — P. 31–39.
  31. Lassen M. R., Ageno W., Borris L. C. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis aft er total knee arthroplasty // N. Engl. J. Med. — 2008. — Vol. 358. — P. 2776–2786.
  32. Turpie A. G., Bauer K. A., Davidson B. et al. Once-Daily Oral Rivaroxaban Compared with Subcutaneous Enoxaparin Every 12 Hours for Th romboprophylaxis aft er Total Knee Replacement: RECORD4. ASH Annual Meeting Abstracts 2008 // Blood. — 2008. — Vol. 112. — Abstract 35.
  33. Gibson C., Mega J., Hammett C. et al. Randomized Comparison of Rivaroxaban, an Oral Direct Factor Xa Inhibitor, with Placebo in Patients with Acute Coronary Syndromes: The ATLAS ACS-TIMI 46 Trial // Circulation. — 2008. — Vol. 118. — P. 2311.
  34. Buller H. R. Once-Daily Oral Rivaroxaban Versus Placebo in the Long-Term Prevention of Recurrent Symptomatic Venous Th romboembolism. Th e Einstein-Extension Study. ASH Annual Meeting Abstracts 2009 // Blood. — 2009. — Vol. 114. — LBA-Abstract 2.
  35. Raghavan N., Frost C. E., Yu Z. et al. Apixaban metabolism and pharmacokinetics aft er oral administration to humans // Drug. Metab. Dispos. — 2009. — Vol. 37. — P. 74–81.
  36. Lassen M. R., Gallus A. S., Pineo G. F. et al. Randomized Double-Blind Comparison of Apixaban with Enoxaparin for Th romboprophylaxis aft er Knee Replacement: Th e ADVANCE-1 Trial. ASH Annual Meeting Abstracts 2008 // Blood. — 2008. — Vol. 112. — Abstract 31.
  37. Lassen M. R., Raskob G. E., Gallus A. et al. Apixaban or enoxaparin for thromboprophylaxis aft er knee replacement // N. Engl. J. Med. — 2009. — Vol. 361. — P. 594–604.
  38. Lassen M. R., Raskob G. E., Gallus A. et al. Apixaban versus enoxaparin for thromboprophylaxis aft er knee replacement (ADVANCE-2): a randomised double-blind trial // Lancet. — 2010. — Vol. 375. — P. 807–815.
  39. Lassen M. R., Davidson B. L., Gallus A. et al. Th e effi cacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement // Th romb. Haemost. — 2007. — Vol. 5. — P. 2368–2375.
  40. Committee A. S. Investigators. Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Th erapy Aft er Acute Coronary Syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial // Circulation. — 2009. — Vol. 119. — P. 2877–2885.
  41. Furugohri T., Isobe K., Honda Y. et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profi les // Th romb. Haemost. — 2008. — Vol. 6. — P. 1542–1549.
  42. Fuji T., Fujita S., Tachibana S. et al. Randomized, Double- Blind, Multi-Dose Effi cacy, Safety and Biomarker Study of the Oral Factor Xa Inhibitor DU-176b Compared with Placebo for Prevention of Venous Th romboembolism in Patients aft er Total Knee Arthroplasty. ASH Annual Meeting Abstracts 2008 // Blood. — 2008. — Vol. 112. — Abstract 34.
  43. Weitz J. J., Connolly S. J., Patel I. et al. Randomized, parallel- group, multicenter, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fi brillation // Th romb. Haemost. — 2010 [in press].
  44. Zhang P., Huang W., Wang L. et al. Discovery of betrixaban (PRT054021), N- (5-chloropyridin-2-yl) — 2- (4- (N, N-dimethylcarbamimidoyl) benzamido) — 5-meth oxybenzamide, a highly potent, selective, and orally effi cacious factor Xa inhibitor // Bioorg. Med. Chem. Lett. — 2009. — Vol. 19. — P. 2179–2185.
  45. Turpie A. G., Bauer K. A., Davidson B. L. et al. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events aft er total knee replacement (EXPERT) // Th romb. Haemost. — 2009. — Vol. 101. — P. 68–76.
  46. Kohrt J. T., Bigge C. F., Bryant J. W. et al. Th e discovery of (2R, 4R) — N- (4-chlorophenyl) — N- (2-fl uoro-4- (2-oxopyridin- 1 (2H) — yl) phenyl) — 4-methoxypyrrolidine- 1,2-dicarb oxamide (PD 0348292), an orally effi cacious factor Xa inhibitor // Chem. Biol. Drug. Des. — 2007. — Vol. 70. — P. 100–112.
  47. Cohen A. T., Armstrong D., Gazdzik T. et al. An Adaptive- Design Dose-Ranging Study of PD 0348292, a New Oral Factor Xa Inhibitor, for Th romboprophylaxis aft er Total Knee Replacement Surgery. ASH Annual Meeting Abstracts 2008 // Blood. — 2008. — Vol. 112. — Abstract 980.
  48. Agnelli G., Haas S., Ginsberg J. S. et al. A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism aft er hip or knee replacement // Th romb. Haemost. — 2007. — Vol. 5. — P. 746–753.
  49. Iwatsuki Y., Shigenaga T., Moritani Y. et al. Biochemical and Pharmacological Profi les of YM150, an Oral Direct Factor Xa Inhibitor. ASH Annual Meeting Abstracts 2006 // Blood. — 2006. — Vol. 108. — Abstract 911.
  50. Eriksson B. I., Turpie A. G., Lassen M. R. et al. A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery // Th romb. Haemost. — 2007. — Vol. 5. — P. 1660–1665.
  51. Eriksson B. I., Turpie A. G. G., Lassen M. R. et al. Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, aft er total hip arthroplasty. A dose fi nding study (ONYX-2) // Th romb. Haemost. — 2010. — Vol. 8. — P. 714–721.
  52. Kawamura M., Konishi N., Katsuhiko H. et al. Eff ects of TAK-442, a Direct FXa Inhibitor, and Fondaparinux on Platelet-Associated Prothrombinase in the Balloon Injured Artery of Rats. ASH Annual Meeting Abstracts 2008 // Blood. — 2008. — Vol. 112. — Abstract 4077.
  53. Konishi N., Hiroe K., Imaeda Y. et al. Diff erential Eff ects of TAK-442, a Factor Xa Inhibitor, and Ximelagatran, a Th rombin Inhibitor, on Bleeding: Possible Role of Diff erences in Eff ects on Factor V–Mediated Feedback on Blood Coagulation Cascade. ASH Annual Meeting Abstracts 2008 // Blood. — 2008. — Vol. 112. — Abstract 5460.
  54. Weitz J. J., Cao C., Eriksson B. et al. Phase II Dose-Finding Study with TAK-442, An Oral Factor Xa Inhibitor, in Patients Undergoing Elective Knee Arthroplasty. ASH Annual Meeting Abstracts 2009 // Blood. — 2009. — Vol. 114. — Abstract 170.
  55. Ellis D. J., Usman M. H., Milner P. G. et al. Th e fi rst evaluation of a novel vitamin K antagonist, tecarfarin (ATI- 5923), in patients with atrial fi brillation // Circulation. — 2009. — Vol. 120. — P. 1029–1035.
  56. Eriksson B. I., Dahl O. E., Lassen M. R. et al. Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study // Th romb. Haemost. — 2008. — Vol. 6. — P. 457–463.
  57. Chan M. Y., Cohen M. G., Dyke C. K. et al. Phase 1b randomized study of antidotecontrolled modulation of factor IXa activity in patients with stable coronary artery disease // Circulation. — 2008. — Vol. 117. — P. 2865–2874.
  58. Cohen M. G., Purdy D. A., Rossi J. S. et al. First clinical application of an actively reversible direct factor IXa inhibitor in elective percutaneous coronary intervention // Eur. Heart J. — 2009. — Vol. 30 (Suppl 1). — P. 686.
  59. Veyrat-Follet C., Vivier N., Trellu M. et al. Th e pharmacokinetics of idraparinux, a long-acting indirect factor Xa inhibitor: population pharmacokinetic analysis from Phase III clinical trials // Th romb. Haemost. — 2009. — Vol. 7. — P. 559–565.
  60. Bousser M. G., Bouthier J., Buller H. R. et al. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fi brillation: a randomised, open-label, non-inferiority trial // Lancet. — 2008. — Vol. 371. — P. 315–321.
  61. Trellu M., Perez Y., Ortiz J. et al. Bioequipotency of idraparinux and biotinylated idraparinux aft er single dose in healthy subjects // Th romb. Haemost. — 2007. — Vol. 5 (Suppl 2). — P. 678.
  62. Buller H. R., Destors J. M., Gallus A. S. et al. Idrabiotaparinux, a Biotinylated Long-Acting Anticoagulant, in the Treatment of Deep Venous Th rombosis (EQUINOX Study): Safety, Effi cacy, and Reversibility by Avidin. ASH Annual Meeting Abstracts 2008 // Blood. — 2008. — Vol. 112. — Abstract 32.
  63. Mueck W., Eriksson B. I., Bauer K. A. et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban — an oral, direct factor Xa inhibitor in patients undergoing major orthopaedic surgery // Clin. Pharmacokinet. — 2008. — Vol. 47. — P. 203–216.
  64. . Lu G., DeGuzman F. R., Lakhotia S. et al. Recombinant Antidote for Reversal of Anticoagulation by Factor Xa Inhibitors. ASH Annual Meeting Abstracts 2008 // Blood. — 2008. — Vol. 112. — Abstract 983.
  65. Melnikova I. Th e anticoagulants market // Nat. Rev. Drug Discov. — 2009. — Vol. 8. — P. 353–354.

— —

www.hemostas.ru Информационный проект
«Гемостаз и реология»
Научное общество
«Клиническая гемостазиология»
 
—
Журнал
«Тромбоз, гемостаз и реология» №2 2017
вышел из печати и разослан подписчикам
Содержание номера
—
Адрес для корреспонденции:
Москва 123104 а/я131
 
По работе сайта:
roitman@hemostas.ru
hemostas@aha.ru
 
Телефон редакции:
(903) 144-46-34
 
Факс редакции:
(495) 699-33-73
 
Подписной индекс
по каталогу
Роспечать»:

18362 — для индивидуальных подписчиков,
18363 — для организаций
 
Подписной индекс
по каталогу «Пресса России»:

83835 — для индивидуальных подписчиков,
83837 — для организаций

Международный
индекс:

ISSN 2078-1008
—
 
Написать веб-мастеру